News News News...
HOUSTON, Jun 13, 2006 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX)
announced
a follow-on order for the production of synDNA(TM) from a client referred
by
Aldevron, LLC (Fargo, ND).
The current order for synDNA(TM) was placed after the initial batch of
synDNA(TM) proved to be the preferred material for use in the manufacture
of
innovative products by the client. While the details of the order were not
disclosed, success in the next, final series of tests could result in
future
orders for gram quantities of custom synDNA(TM) material to satisfy the
client's
anticipated demand.
"The CytoGenix synDNA(TM) technology is ideally suited for many of our
clients
when conventional plasmid DNA is too costly or difficult to produce,"
stated
Michael Chambers, President and CEO of Aldevron. "The first order of
synDNA(TM)
met and exceeded our expectations in terms of quality, cost, and
turn-around
time."
"The relationship between CytoGenix and Aldevron continues to be mutually
beneficial," said Malcolm Skolnick, President and CEO of CytoGenix. "We
are
delighted to service clients by utilizing our excess production capacity
thereby
generating revenue to fund our internal product development programs."
AI
